Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097
Debt
Debt-to-Equity RatioN/A
Current Ratio6.95
Quick Ratio6.95
Price-To-Earnings
Trailing P/E Ratio-3.73
Forward P/E Ratio-10.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.28 million
Price / Sales316.46
Cash FlowN/A
Price / CashN/A
Book Value$1.96 per share
Price / Book6.97
Profitability
EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-1,665.11%
Return on Equity-123.72%
Return on Assets-61.06%
Miscellaneous
Employees44
Outstanding Shares52,820,000
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.57. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analysts' expectations of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
7 Wall Street analysts have issued 12 month target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $14.20 in the next year. View Analyst Ratings for Dicerna Pharmaceuticals.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Portola Pharmaceuticals (PTLA), Ascendis Pharma A/S (ASND), TESARO (TSRO), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Enanta Pharmaceuticals (ENTA), Akcea Therapeutics (AKCA), Xencor (XNCR), Global Blood Therapeutics (GBT), Arena Pharmaceuticals (ARNA) and Endo International (ENDP).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
- Mr. John B. Green, Chief Financial Officer (Age 64)
- Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)
- Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
- Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71)
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
News headlines about DRNA stock have been trending somewhat negative recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of -0.07 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Dicerna Pharmaceuticals' major shareholders?
Dicerna Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Which major investors are selling Dicerna Pharmaceuticals stock?
Which major investors are buying Dicerna Pharmaceuticals stock?
DRNA stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $13.66.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $721.02 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
